

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

Parental paediatric information sheet and consent form

Study Title: Optimising DTP-Containing Vaccine Infant Immunisation Schedules in Uganda.

Internal Reference Number / Short title: 2019-04 /OPTIMMS-Uganda

Investigational medication: WHO EPI Vaccines

Sponsor: University of Oxford

Funder: The Bill and Melinda Gates Foundation

Investigator: Prof Alison Elliott

Why are vaccines important?


Vaccines help protect our bodies against diseases. When a child comes into contact with a disease against which they have been vaccinated, their body will be able to recognise and fight the disease. Without vaccines, children are at increased risk of catching many serious diseases.

Why do we want to do a study?

The World Health Organization (WHO) recommends that all children receive a number of different vaccines at specific ages. One of the vaccines recommended protects against 5 diseases called diphtheria, tetanus, whooping cough, hepatitis and a bug called *Haemophilus influenzae* type b (Hib) which can cause pneumonia and meningitis. This vaccine is sometimes called a DTP-containing vaccine. Many countries around the world give this vaccine at different time points and it is not known which schedule is best.

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott



MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

The purpose of this study is to help identify the best possible schedule or schedules, which will provide the best level of protection against the diseases in the DTP-containing vaccine when children are young. To do this, the DTP-containing vaccine will be given according to 5 different schedules, with a booster at 9 or 12 months of age. All of these schedules have been proven safe and effective. The 5 schedules will be compared to see if any one schedule is better than the others. The results of this study will be used to make informed clinical decisions to help develop potential new childhood vaccination schedules

Your child will receive all the other vaccines and medications which are currently given routinely; Polio vaccines, Pneumococcal vaccine, Rotavirus vaccine, Measles and Rubella vaccine, Vitamin A supplementation and deworming. Additionally, we will give vaccines for typhoid, yellow fever and chicken pox. The study doctor/nurse will talk to you about all the vaccines that your child receives. All vaccines will be given according to the different schedules (See table 1)


The study will be conducted in 2 countries (Uganda and Nepal). Approximately 900 babies will be enrolled in each country.

What does the study involve?

If you decide that you want your child to take part, you will be asked to sign an informed consent form. You will be given a copy of the signed form to keep, and the original will stay at the study centre.

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott



MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | +256 (0) 393 262910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials


The study consists of 2 parts; the main study (Table 1) and the booster study (Table 2). During the study, you and your child will attend up to 10 visits at the study centre over a 2-year period, depending on the vaccination schedule your child is allocated to. The study team will also monitor the growth of your child and draw no more than 4 samples of blood to assess the body's response to the vaccine.

At the first visit, the study doctor will record your child's date of birth, gender and race/ethnicity and ask you some questions about your child's medical history and current health status. Your child will be assigned to a study vaccination schedule group and one of 4 booster groups. He/she will have an equal chance of being assigned to any of the different vaccine schedules and booster groups. This will be determined at random by a computer. No one will influence which schedule your child follows during the study. We will explain in more detail the schedule your child has been allocated to. Your child will then either receive their first set of vaccines or be asked to come back at 8 weeks of age. The study doctor/nurse will give you a health card and this will show the different time points your child will come for study visits.

At each study visit a physical examination will be performed to check your child's overall health; if needed they will take a blood sample and give any vaccines that are due. The study doctor will also ask about any changes in your child's health and usual medications since the last study visit.

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English


Principal Investigator: Prof Alison Elliott



Approved by IRB on:

MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute |
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | +256 (0) 393 262910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

Table 1: Main study: 5 vaccines schedules


Schedule One			
6 weeks	10 weeks	14 weeks	
Consent & randomisation			
DTP-containing vaccine Pneumococcal vaccine Oral polio vaccine Rotavirus vaccine	DTP-containing vaccine Oral polio vaccine Rotavirus vaccine	DTP-containing vaccine Pneumococcal vaccine Oral & injectable polio vaccine	

Schedule Two			
6 weeks	10 weeks	14 weeks	
Consent & randomisation			
DTP-containing vaccine Pneumococcal vaccine Oral polio vaccine Rotavirus vaccine	Oral polio vaccine	DTP-containing vaccine Pneumococcal vaccine Oral & injectable polio vaccine Rotavirus vaccine	

Schedule Three			
6 weeks	8 weeks	16 weeks	20 weeks
Consent & randomisation	DTP-containing vaccine Pneumococcal vaccine Oral polio vaccine Rotavirus vaccine	DTP-containing vaccine Pneumococcal vaccine Oral & injectable polio vaccine Rotavirus vaccine	Oral polio vaccine

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott



MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute |
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | +256 (0) 393 262910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--


Initials

Schedule Four			
6 weeks	8 weeks	12 weeks	16 weeks
Consent randomisation	& DTP-containing vaccine Pneumococcal vaccine Oral polio vaccine Rotavirus vaccine	DTP-containing vaccine Oral polio vaccine Rotavirus vaccine	DTP-containing vaccine Pneumococcal vaccine Oral & injectable polio vaccine

Schedule Five			
6 weeks	8 weeks	16 weeks	24 weeks
Consent randomisation	& DTP-containing vaccine Pneumococcal vaccine Oral polio vaccine Rotavirus vaccine	DTP-containing vaccine Pneumococcal vaccine Oral & injectable polio vaccine Rotavirus vaccine	DTP-containing vaccine Oral polio vaccine

Table 2: Booster study: 4 booster groups


Booster Group 1				
9 months	10 months		18 months	24 months
DTP-containing vaccine Measles & Rubella vaccine Pneumococcal vaccine	Typhoid vaccine Yellow fever vaccine		Measles & Rubella vaccine	Varicella vaccine



Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

Booster Group 2				
9 months	12 months	13 months	18 months	24 months
Measles & Rubella vaccine Pneumococcal vaccine	DTP-containing vaccine Yellow fever vaccine	Typhoid vaccine	Measles & Rubella vaccine	Varicella vaccine

Booster Group 3				
9 months	12 months	13 months	18 months	24 months
Measles & Rubella vaccine Pneumococcal vaccine	DTP-containing vaccine Typhoid vaccine	Yellow fever vaccine	Measles & Rubella vaccine	Varicella vaccine


Booster Group 4				
9 months	12 months	13 months	18 months	24 months
Measles & Rubella vaccine Pneumococcal vaccine	DTP-containing vaccine Typhoid vaccine Yellow fever vaccine		Measles & Rubella vaccine	Varicella vaccine

What will happen to any samples your child gives?

As part of the study your child will have a total of 4 blood draws over 2 years. Table 3 below shows possible timings for each blood draw. The exact timing of each blood draw will be allocated at your first visit. We will take no more than 5mls (1 teaspoon) of blood each time. Your child's samples will be labelled with a code that will allow your child's identity to be anonymised.

Parental paediatric ICF, Version 2.1, 17 Feb 2020 English


Principal Investigator: Prof Alison Elliott



Approved by IRB on:

MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute |
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | +256 (0) 393 262910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

Table 3: Blood draw timing


Blood draw timing			
Blood 1	Blood 2	Blood 3	Blood 4
6-24 weeks	24 weeks -28 weeks	9 months or 12 months	10 months – 24 months

All blood samples will be stored in a secure facility by MRC/UVRI and LSHTM Uganda Research Unit's Masaka lab and half of your child's sample will be shipped to laboratories in Europe for tests to help understand how well the vaccines work. The other half will remain in the secure facility in Masaka or in Entebbe. At the end of the study, anonymised left-over samples sent to Europe will be destroyed. If you give permission the remaining sample stored in Uganda will be stored for future research after the end of the study. If you do not give your permission the sample will be destroyed at the end of the study. No additional tests will be performed without the approval of the UVRI Research Ethics Committee (UVRI REC). The name and address of the laboratory:

1. MRC/UVRI and LSHTM Uganda Research Unit
Plot 2-5 Ntikko Road, Masaka
P.O. Box 49 Entebbe, Uganda
2. National Institute for Public Health and the Environment (RIVM)
Antonie van Leeuwenhoeklaan 9
3721 MA Bilthoven
The Netherlands
3. Oxford Vaccine Group
Centre for Vaccinology & Tropical Medicine
Churchill Hospital
Oxford, OX3 7LE, UK

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott



MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

At any time during the study or after the study has finished you may ask for your samples to be destroyed. Information obtained from the samples will continue to be kept and used for the purposes agreed by you in this document.

What are the possible disadvantages or risks of taking part?

Most children who receive vaccines remain entirely well. There are no additional risks beyond those that are normally possible with routine immunisations. These may include redness, swelling and pain at the site of injection and some irritability, sleepiness or reduced feeding. Children can develop a fever and may develop some vomiting or diarrhoea. There have been very rare reports of prolonged crying, rashes and allergic reactions. The study staff are trained and equipped to deal with these.


There is a potential risk of whooping cough as a result of the reduced dose schedule. All whooping cough-like illness' will be recorded, followed, and treated, by study clinicians. The symptoms of whooping cough include a running cough, low grade fever and later, fits of many rapid coughs, followed by a high-pitched "whooping" sound. Others include vomiting during or after coughing fits, exhaustion after coughing fits.

The blood test may be uncomfortable, however, creams will be offered to minimise discomfort. After the blood draw there may be a small bruise which should fade in a few days.

What are the possible benefits of taking part in this study?

Parental paediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott



Approved by IRB on:

MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute |
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | +256 (0) 393 262910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

During the study your child will receive the routine vaccines in the Uganda vaccine programme and those that are currently not available free of charge (typhoid, varicella, yellow fever vaccine and measles-rubella vaccine).

If your child has a fever or other symptoms of illness during the 2 years of the trial, they will be able to access free routine medical care and treatment. You will receive 10,000 UGX for time you spend at the study clinic, 20,000 UGX for transport reimbursement and 10,000 UGX for your meals for each scheduled clinic visit.


What else do I need to know?

All information collected during the study will remain confidential. Your child's samples and study data will be identified by a number rather than their name. If you decided to take part, representatives of the ethics committee and regulatory authorities may read your child's study records to check that the study is being carried out properly. The results of your child's tests and the information we collect about your child (also called study data) will be shared with other researchers in other countries. We will not tell anyone yours or your child's name or where you live. Your child's privacy and personal information will be protected using measures which follow the requirements in Uganda. The data collected will be used for research related to infection and immunity. We will inform you of any changes to the study.

If your child is admitted to hospital at any point during the study please contact the study doctor Dr Mary Nyantaro on telephone number +256 788 323435.

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott



MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

Taking part in this study is entirely voluntary, and you can withdraw from the study at any time by contacting the research team at the hospital. You do not need to give a reason and it will not affect your child's routine care and your child will receive their vaccines in the normal way. If you choose to withdraw from the study we will make sure your child completes the routine vaccine programme. We will still use the information you gave us before your withdrawal.

The study sponsor has insurance to cover the costs of research-related injuries providing that your child followed all the instructions and advice of the study doctor and did nothing to cause or contribute to the research-related injury. The study sponsor may also compensate your child in accordance with the law of Uganda and by signing this form, you do not give up any legal right your child may have.


Results of the study will be available to you, after the study ends please talk to the study doctor.

What if you have a question? / Who should you contact for more information?

If you or your child have a question, concern or complaint about any aspect of this study, you should ask the study doctor on telephone number +256 788 323435 or a member of the research team who will do their best to help or you can visit our office located at MRC/UVRI & LSHTM Uganda Research Unit Masaka site, Plot 2-5 Ntikko Road Masaka Town or contact the Principal Investigators, Prof Alison Elliott on Phone number: +256 417 704000 or Dr Freddie Mukasa Kibengo on +256 772 435251. If you have questions about your child's rights as part of the research, or concerns or

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott



MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute |
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | +256 (0) 393 262910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

complaints about the research that you do not wish to discuss with the study doctor or research team, you may contact the Chairperson of UVRI REC, Dr Tom Lutalo on telephone number: 0414 321962/ 0716321962 at the at Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, Entebbe,


By signing this consent form, you are giving permission for the processing and use of your child's personal information for this study.

On behalf of your child, you may use their rights under local data protection laws to access, correct their Personal Data and object to any further processing of their Personal Data by applying in writing to the study doctor. Please note that, once your child commences the study, the data collected cannot be deleted for a number of years due to legal requirement to retain the data for 15 years.

University of Oxford is organising this study as the study sponsor and is responsible for your child's anonymised study data in accordance with applicable Data Protection laws. The study doctor's Institution is responsible for their handling of your child's Personal Data collected as part of this study.

Who has reviewed the study?

This study has been reviewed and approved by the Uganda Virus Research Institute Research Ethics Committee (UVRI REC), the Sponsor, Regulatory Authorities.



Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott

Approved by IRB on:

MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute |
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | +256 (0) 393 262910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE




--	--	--	--	--	--	--

Participant ID

--	--	--

Initials



Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott

Approved by IRB on:

MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute |
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | +256 (0) 393 262910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

Informed Consent form

Study title: Optimising DTP-containing vaccine infant immunisation schedules in Uganda

Study drug: WHO-EPI infant vaccines

Sponsor of the study: University of Oxford

Investigator: Prof Alison Elliott

I confirm the following:

- I have read the information sheet for the above study or it has been read to me, and have had an adequate time to think about my child taking part.
- I voluntarily agree that my child can be part of this research study, to follow the study procedures and to provide necessary information to the study doctor, or other staff members, as requested.
- I understand that I may freely choose to withdraw my child from this study at any time without giving a reason and without my child's medical care or legal rights being affected.
- I have received a copy of this information sheet and consent form to keep for myself.
- If the study doctor is not our family doctor, he/she may inform my family doctor about my child taking part in this study and request medical information about my child.

Parent initial

Parent initial


Parent initial

Parent initial

Parent initial

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott



MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

- I agree to my child's samples being taken and used as described in this information sheet for mandatory analysis as part of the study.
- By signing this information and consent form I agree that my child's anonymised study data, can be used as described in this consent form, including transfer to countries outside of Uganda for the purposes set out in the 'How will your child's personal information be used?' part of this form.
- I understand I may also be contacted at a later date(s) for my permission in connection with this study or any related sub-study.
- I agree that my child's anonymised study data can be used and shared by University of Oxford and other researchers for additional research.
- I understand that information about the study results will be made available after the end of the study.

Parent initial


Parent initial

Parent initial

Parent initial

Parent initial

By signing this document, I agree that my child will take part in this study, as set out in this information sheet and consent form.



Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott

Approved by IRB on:

MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute |
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417 704000 | +256 (0) 393 262910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

PARENT'S CONSENT TO CHILD'S PARTICIPATION

My signature (or thumbprint or ID mark) below confirms that I have read this document or this document has been read to me and I agree that my child will take part in this study, as set out in this information sheet and consent form.

Name of the child:

<u>Parent's Name</u>	<u>Parent's Signature/Thumbprint/ID mark</u>	<u>Date</u>

Investigator/Designee

I, the undersigned, have fully and carefully explained the study to this child's parent/guardian and certify that to the best of my knowledge, they clearly understand the nature, risks and benefits of his/her child's participation in this study.


I confirm that the child's parent/guardian was given an opportunity to ask questions about the study, and all the questions asked by them have been answered correctly and to the best of my ability.

I confirm that they have not been forced into giving consent, and the consent has been given freely and voluntarily.

A copy of this Information and Consent Form has been provided to the child's parent/guardian.

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott



Approved by: IBB BOX 49, ENTEBBE

MRC/UVRI and LSHTM Uganda Research Unit | C/O Uganda Virus Research Institute | UGANDA
Plot 51- 59 Nakiwogo Road - Entebbe | P.O Box 49 Entebbe | Tel: +256 (0) 417-704000 | +256 (0) 393-202910/1
Email: mrc@mrcuganda.org | Website: www.mrcuganda.org

MRC/UVRI and LSHTM Uganda Research Unit



Uganda
Virus
Research
Institute

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



--	--	--	--	--	--	--

Participant ID

--	--	--

Initials

Print name of person conducting the informed consent discussion

Signature of person conducting the
Informed consent discussion

Date

*If the participant, parent or guardian is unable to read and/or write, an impartial witness should be present during the informed consent discussion. After the written informed consent form is read and explained to the parent or guardian, and after they have orally consented to their child's participation in the trial, and have either signed the consent form or provided their fingerprint, the witness should sign and personally date the consent form. By signing the consent form, the witness attests that the information in the consent form and any other written information was accurately explained to, and apparently understood by parent or guardian, and that informed consent was freely given by the parent or guardian.

Name of Person Witnessing Consent (printed)

Signature of Person Witnessing Consent

Date

Parental pediatric ICF, Version 2.1, 17 Feb 2020 English

Principal Investigator: Prof Alison Elliott

